Skip to main content
SpringerLink
Log in

Indikation von CRS und HIPEC bei peritonealen Metastasen von Ovarialkarzinomen

  • Chapter
Peritoneale Tumoren und Metastasen

  • 1640 Accesses

Zusammenfassung

Das Ovarialkarzinom wird in drei Viertel der Fälle in einem fortgeschrittenen Stadium erkannt, sodass bei der Mehrzahl der Patientinnen bereits eine großflächige peritoneale Karzinose vorherrscht. Diese muss operativ abgetragen werden, denn die Entfernung aller sichtbaren Tumorläsionen ist mit einem deutlich besseren Gesamtüberleben assoziiert. Trotz einer kompletten Zytoreduktion verbleiben oft kleine sichtbare Läsionen sowie mikroskopische und somit nicht sichtbare Tumorläsionen im Peritoneum. Um diese mikroskopischen Tumorreste zu behandeln, wurde das Konzept einer postoperativen intraperitonealen Chemotherapie entwickelt, das in mehrfachen Studien zu einer weiteren Verbesserung des Gesamtüberlebens führte. Somit erscheint der Einsatz der HIPEC beim Ovarialkarzinom sinnvoll. Trotz zahlreicher Phase-I- und -II-Studien, die eine gute Durchführbarkeit demonstrierten, gibt es bisher keine verlässlichen Überlebensdaten, die einen Vorteil der HIPEC gegenüber einer klassischen kompletten Zytoreduktion zeigen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Alberts DS, Liu PY, Hannigan EV, et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950–1955

    Article  CAS  Google Scholar 

  • Ansaloni L, Agnoletti V, Amadori A, et al. (2012) Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 22: 778–785

    Article  Google Scholar 

  • Ansaloni L, Coccolini F, Morosi L, et al. (2015) Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Br J Cancer 112: 306–312

    Article  Google Scholar 

  • Armstrong DK, Bundy B, Wenzel L, et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34–43

    Article  CAS  Google Scholar 

  • Barakat RR, Sabbatini P, Bhaskaran D, et al. (2002) Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol 20: 694–698

    Article  Google Scholar 

  • Burger RA, Brady MF, Bookman MA, et al. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: 2473–2483

    Article  CAS  Google Scholar 

  • Chi DS, McCaughty K, Diaz JP, et al. (2006) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106: 1933–1939

    Article  Google Scholar 

  • Coccolini F, Campanati L, Catena F, et al. (2015) Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol 26: 54–61

    Article  Google Scholar 

  • de Bree E, Rosing H, Filis D, et al. (2008) Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann Surg Oncol 15: 1183–1192

    Article  Google Scholar 

  • Dedrick RL (1985) Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12: 1–6

    Google Scholar 

  • Fujiwara K, Armstrong D, Morgan M, et al. (2007) Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer 17: 1–20

    Article  CAS  Google Scholar 

  • Giovanella BC, Stehlin JS Jr, Morgan AC (1976) Selective lethal effect of supranormal temperatures on human neoplastic cells. Cancer Res 36: 3944–3950

    Google Scholar 

  • Glehen O, Mithieux F, Osinsky D, et al. (2003) Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 21: 799–806

    Article  CAS  Google Scholar 

  • Goff BA, Mandel LS, Drescher CW, et al. (2007) Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 109: 221–227

    Article  Google Scholar 

  • Gore M, du Bois A, Vergote I (2006) Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 24: 4528–4530

    Article  Google Scholar 

  • Harter P, Hahmann M, Lueck HJ, et al. (2009) Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 16: 1324–1330

    Article  CAS  Google Scholar 

  • Helm CW (2009) The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist 14: 683–694

    Article  CAS  Google Scholar 

  • Hettinga JV, Lemstra W, Meijer C, et al. (1997a) Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells. Br J Cancer 75: 1735–1743

    Article  CAS  Google Scholar 

  • Hettinga JV, Konings AW, Kampinga HH (1997b) Reduction of cellular cisplatin resistance by hyperthermia – a review. Int J Hyperthermia 13: 439–457

    Article  CAS  Google Scholar 

  • Janicke F, Holscher M, Kuhn W, et al. (1992) Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70: 2129–2136

    Article  Google Scholar 

  • Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573–584

    Article  CAS  Google Scholar 

  • Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol 177: 1053–1064

    Article  Google Scholar 

  • Lentz SS, Miller BE, Kucera GL, et al. (2007) Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma. Gynecol Oncol 106: 207–210

    Article  CAS  Google Scholar 

  • Los G, Mutsaers PH, Lenglet WJ, et al. (1990) Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 25: 389–394

    Article  CAS  Google Scholar 

  • Los G, Verdegaal EM, Mutsaers PH, et al. (1991) Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol 28: 159–165

    Article  CAS  Google Scholar 

  • Markman M (2007) Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action. J Clin Oncol 25: 4168–4170

    Article  Google Scholar 

  • Markman M, Bundy BN, Alberts DS, et al. (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19: 1001–1007

    Article  CAS  Google Scholar 

  • Oseledchyk A, Zivanovic O (2015) Intraoperative Hyperthermic Intraperitoneal Chemotherapy in Patients With Advanced Ovarian Cancer. Oncology (Williston Park) 29: 695–701

    Google Scholar 

  • Panteix G, Beaujard A, Garbit F, et al. (2002) Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res 22: 1329–1336

    Google Scholar 

  • Piso P, Dahlke MH, Ghali N, et al. (2007) Multimodality treatment of peritoneal carcinomatosis from colorectal cancer: first results of a new German centre for peritoneal surface malignancies. Int J Colorectal Dis 22: 1295–1300

    Article  CAS  Google Scholar 

  • Reed E, Parker RJ, Gill I, et al. (1993) Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res 53: 3694–3699

    Google Scholar 

  • Royer B, Guardiola E, Polycarpe E, et al. (2005) Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. Anticancer Drugs 16: 1009–1016

    Article  CAS  Google Scholar 

  • Speyer JL, Sorich J (1992) Intraperitoneal carboplatin: rationale and experience. Semin Oncol 19: 107–113

    Google Scholar 

  • Spiliotis J, Halkia E, Lianos E, et al. (2015) Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study. Ann Surg Oncol 22: 1570–1575

    Article  Google Scholar 

  • Torre LA, Bray F, Siegel RL, et al. (2012) Global cancer statistics. CA Cancer J Clin 65: 87–108

    Google Scholar 

  • van de Vaart PJ, van der Vange N, Zoetmulder FA, et al. (1998) Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 34: 148–154

    Google Scholar 

  • Walker J, Brady MF, Di Silvestro PA, Fujiwara K, Alberts D, Zheng W, Tewari K, Cohn DE, Powell M, Van Le L, Rubin S, Davidson SA, Gray HJ, Waggoner S, Myers T, Aghajanian C, Secord AA, Mannela RS (2017) A Phase Iii Trial of Bevacizumab with Iv Versus Ip Chemotherapy for Ovarian, Fallopian Tube, and Peritoneal Carcinoma: An Nrg Oncology Study. 47th Annual Meeting of the Society of Gynecologic Oncology 2017, Late-breaking Abstract Session, #6918

    Google Scholar 

  • Zivanovic O, Abramian A, Kullmann M, et al. (2015) HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer 136: 699–708

    Google Scholar 

  • Zivanovic O, Aldini A, Carlson JW, et al. (2009) Advanced cytoreductive surgery: American perspective. Gynecol Oncol 114: S3-S9

    Article  Google Scholar 

  • Zivanovic O, Sima CS, Iasonos A, et al. (2010) The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. Gynecol Oncol 116: 351–357

    Article  Google Scholar 

  • Zylberberg B, Dormont D, Janklewicz S, Darai E, Bretel JJ, Poncelet C, Guillet JL, Madelenat P (2001) Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer. Eur J Gynaecol Oncol 22: 40–45. PMID: 11321492

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Memorial Sloan Kettering Cancer Center, Gynecology Service, Department of Surgery, York Avenue 1275, 10065, New York, USA

    MD, Prof. Dr. med. O. Zivanovic

  2. Memorial Sloan Kettering Cancer Center, Department of Radiology, York Avenue 1275, 10065, New York, USA

    A. Oseledchyk

Authors
  1. MD, Prof. Dr. med. O. Zivanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Oseledchyk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to O. Zivanovic or A. Oseledchyk .

Editor information

Editors and Affiliations

  1. Charité Campus Virchow-Klinikum, Berlin, Deutschland

    Beate Rau

  2. Krankenhaus Barmherzige Brüder, Regensburg, Deutschland

    Pompiliu Piso

  3. Universitätsklinikum Tübingen, Tübingen, Deutschland

    Alfred Königsrainer

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland

About this chapter

Cite this chapter

Zivanovic, O., Oseledchyk, A. (2018). Indikation von CRS und HIPEC bei peritonealen Metastasen von Ovarialkarzinomen. In: Rau, B., Piso, P., Königsrainer, A. (eds) Peritoneale Tumoren und Metastasen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54500-3_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-54500-3_22

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-54499-0

  • Online ISBN: 978-3-662-54500-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation